期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

三维荧光光谱二阶校正方法测定血浆样中喷昔洛韦及泛昔洛韦含量 被引量：1

Determination of Famciclovir and Penciclovir in human plasma samples by using excitation-emission matrix fluorescent spectra coupled with second-order calibration
原文传递
导出
摘要 利用三维荧光光谱即激发发射矩阵荧光光谱与化学计量学的基于平行因子分析(PARAFAC)算法的二阶校正方法相结合,尝试对血浆样中泛昔洛韦及其活性代谢物喷昔洛韦的含量进行同时定量测定.当算法选取组分数为3时,解析得到血浆样中泛昔洛韦和喷昔洛韦的平均回收率分别为(102.4±3.4)%和(105.1±2.3)%.结果表明该分析策略可准确可靠地实现血浆样中泛昔洛韦和喷昔洛韦的直接同时快速定量测定. Famciclovir and Pencilovir contents in human plasma samples have been tried to determine simultaneously by using second-order calibration method based on Parallel Factor Analysis （FAFARAC） algorithm combined with excitation-emission matrix fluorescent spectra. When the component number in the case was set to 3,the average recoveries of Famciclovir and Penciclovir in human plasma samples were （102.4±3.4）% and （105.1±2.3）% ,respectively. The satisfactory results showed that the second-order calibration method can be applied to quantify Famciclovir and Penciclovir in human plasma samples.
作者 宋晶晶 吴海龙 于永杰 黄蕾 俞汝勤
机构地区 化学生物传感与计量学国家重点实验室 湖南大学化学化工学院
出处 《中国科学：化学》 CAS CSCD 北大核心 2010年第8期1136-1141,共6页 SCIENTIA SINICA Chimica
基金 国家自然科学基金(20775025) 教育部长江学者和创新团队发展计划基金资助
关键词 二阶校正 平行因子分析算法 激发发射矩阵荧光光谱 喷昔洛韦 泛昔洛韦 血浆样 second-order calibration Parallel Factor Analysis algorithm excitation-emission fluorescent spectra Penciclovir Famciclovir plasma samples
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献18

  • 1Hussein ITM, Menashy RV, Field HJ. Penciclovir is a potent inhibitor of feline herpesvirus-1 with susceptibility determined at the level of virus-encoded thymidine kinase. Antiviral Res, 2008, 78:268--274.
  • 2Andrei G, Clercq ED, Snoeck R. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir? Antiviral Res, 2004, 61: 181--187.
  • 3Clercq ED. Antiviral drugs in current clinical use. J Clin Virol, 2004, 30:115--133.
  • 4Zhu WW, Yu AH, Wang WH, Dong RQ, Jun W, Zhai GX. Formulation design of microemulsion for dermal delivery of penciclovir, lnt J Pharm, 2008, 360:184--190.
  • 5冷玲颖,蔡志强,孙铁民.核苷类抗病毒前药的研究进展[J].中国药物化学杂志,2008,18(4):310-316. 被引量：20
  • 6Dao YJ, Jiao Z, Zhong MK. Simultaneous determination of aciclovir, ganciclovir, and penciclovir in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr B, 2008, 867:270--276.
  • 7Lee HW, Seo JH, Lee KT. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry for the determination of penciclovir in human plasma: application to a bioequivalence study. J Chromatogr B, 2007, 852:382--388.
  • 8Schertkel F, Rudaz S, Daali Y, Oestreicher MK, Veuthey JL, Dayer P. Development and validation of a new reversed-phase ion pairing liquid chromatographic method with fluorescence detection for penciclovir analysis in plasma and aqueous humor. J Chromatogr B, 2005, 826:1-7.
  • 9邓鸣,侯艳宁,王金.泛昔洛韦分散片人体生物等效性研究[J].中国医药工业杂志,2006,37(11):756-758. 被引量：4
  • 10Sanchez E, Kowalski BR. Tensorial resolution: a direct trilinear decomposition. J Chemometr, 1990, 4:29--45.

二级参考文献38

  • 1TAN X L, CHU C K, BOUDINOT F D. Development and optimization of anti-HIV nucleoside analogs and prodrugs:a review of their cellular pharmacology, structureactivity relationships and pharmaookinetics[J ]. Adv Drug Deliv Rev, 1999, 39(2) : 117 - 151.
  • 2PARANG K, WIEBE L I, KNAUS E E. Novel approaches for designing 5'-O-ester prodrugs of 3'-azi- do-2', 3'-dideoxythymidine (AZT) [J ]. Curr Med Chem, 2000, 7(10) :995 - 1039.
  • 3MAZIASZ, TIMOTHY. Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxy- genase-2 selective inhibitors and antiviral agents:US, 2005/026902 A1[P ]. 2005 - 02 - 03.
  • 4CAROLE A, GILLES Q, FLORENCE S, et al. New antiviral nueleoside prodrugs await application [ J ]. Curr Med Chem, 2003, 10(18) : 1825 - 1843.
  • 5ERIK D C, HUGH J F. Antiviral prodrugs-the development of successful prodrug strategies for antiviral chemotherapy[J]. Br J Pharmacol, 2006, 147 ( 1 ): 1-11.
  • 6LAVIE A, SCHLICHTING L, VE-TFER I R, et al. The bottleneck in AZT activation[ J ]. Nat Med, 1997, 3 (8) : 922 - 924.
  • 7NAESENS L, BALZARINI J, BISCHOFBERGER N, et al. Antiretroviral activity and pharmacokinetics in mice of oral his (pivaloyloxyrnethyl)-9-(2-phosphonylmethoxyethyl ) adenine, the bis (pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl ) adenine [ J ]. Antimicrob Agents Chemother, 1996, 40(1) :22 - 28.
  • 8DELANEY, WILLIAM E. Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil [ J ]. J Antimicro Chemother, 2007, 59 (5) :827 - 832.
  • 9NAESENS L, BISCHOFBERGER N, AUGUSTIJNS P, et al. Antiretroviral efficacy and pharmaeokinetics CLERCQ of oral bis(isopropyloxycarbonyloxymethyl)- 9-( 2-phosphonyl-methoxypropyl ) adenine in mice [J ]. Antimicrob Agents Chemother, 1998, 42 ( 7 ) : 1568 - 1573.
  • 10NAESENS L, BISCHOFBERGER N, AUGUSTIJNS P, et al. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the bio-chemical barrier by defined ester mixtures [J]. Drug Metab Disp, 2002, 30 (8) : 924 - 930.

共引文献22

同被引文献37

引证文献1

二级引证文献4

中国科学：化学
2010年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部